RIBOXX PHARMACEUTICALS and TOLLYS S.A.S announce an exclusive license agreement for treatment of Toll-like 3 positive cancers

RIBOXX PHARMACEUTICALS and TOLLYS S.A.S announce an exclusive license agreement for treatment of Toll-like 3 positive cancers

Go back

Cookies faciliate the providing of our online services. By using our online services, you agree to our use of cookies.